The U.S. FDA authorized the vaccine Nuvaxovid by Novavax, restricting its use to adults aged 65 and above and those over 12 years with at least one underlying disease that elevates their risk owing to the illness.
The FDA intended to decide on Nuvaxovid’s clearance by April 1 but failed to meet the deadline, rekindling apprehensions among the medical community over the significant regulatory changes implemented by President Donald Trump and his health secretary, renowned vaccine critic Robert F. Kennedy Jr.
Kennedy secured confirmation from the Senate for his position, in part, by pledging to maintain the nation’s immunization schedule. Since assuming office, he has pledged to examine child vaccinations, canceled meetings of professional vaccine advisors, and instructed authorities to reexamine the purported link between vaccines and autism, a correlation that has already been discredited.
According to BTIG evaluator Thomas Shrader, the illnesses specified on the label are clinically uncommon but align with the current discourse.
The vaccine’s future became uncertain when the FDA failed to meet its April 1 deadline for approval of the protein-based vaccine, which contrasts with the messenger RNA-based alternatives from Pfizer and Moderna.
William Schaffner, an instructor of infectious illnesses at Vanderbilt University Medical Center, said that the approval would provide a comforting option for those who are wary about mRNA vaccines.
However, it was rather unusual for the FDA to establish age ranges and use conditions, since this is typically under the oversight of the advisory committee of the Centers for Disease Control and Prevention, he said.
Novavax anticipates readiness for commercial vaccine distribution in the U.S. this autumn, in collaboration with France’s Sanofi, contingent upon strain recommendation.
Novavax, in conjunction with its rivals, must get further authorization to modify the viral strain targeted by its vaccine for the next vaccination season. The subject is scheduled for deliberation at an event of FDA vaccine advisors in the near future.
The FDA has requested that Novavax do post-marketing studies with patients aged 50 to 64 who do not have high-risk factors for severe COVID-19. The vaccine manufacturer is collaborating with Sanofi to evaluate financing and implementation of this new study, it said.
The complete approval prompted a $175 million milestone payout from Sanofi to Novavax.
